Group 1 - The core viewpoint of the article highlights the significant increase in sales of flu medications, particularly Oseltamivir and Baloxavir, amid rising flu activity across multiple regions in China [1] - Dongyangguang Pharmaceutical (06887) experienced a stock price increase of over 4%, reaching HKD 44.12, with a trading volume of HKD 11.73 million [1] - The sales growth rate for Oseltamivir over the past week was reported at 237%, while Baloxavir saw an increase of 180% [1] Group 2 - Dongyangguang Pharmaceutical is recognized as the "king of flu medications," with its Oseltamivir (brand name: Kewai) holding a significant market share in China, particularly in the pediatric segment [1] - The overall sales revenue for Dongyangguang Pharmaceutical is projected to reach CNY 1.301 billion in the first half of 2025 [1]